Stiff person syndrome is a rare autoimmune condition that attacks the central nervous system, causing severe rigidity and painful muscle spasms. Doctors at the Mayo Clinic in Rochester have reported "exciting" results from a trial of CAR-T cell therapy, a treatment already used to fight cancer. The team reprogrammed patients’ own T cells to wipe out disease-causing cells, prompting dramatic improvements in daily function. Patients who previously needed help with basic tasks regained their ability to walk and work. These findings, published in Jama Neurology, suggest a new path for a condition that has no cure despite decades of research.
Early clinical outcomes
Dr Anastasia Zekeridou noted that existing treatments rarely restore previous levels of function, making these early results particularly encouraging. Jonathan Walden, a trial participant, had reached a point where walking required family assistance before receiving the therapy. He now returns to work every day and resumes hobbies like hunting and fishing without experiencing any episodes since treatment. Shari St Germain, another patient, suffered from severe leg cramps and falls but reported feeling "better and better" after the procedure. She described waking up one day feeling good enough to walk on a treadmill for seven minutes, an achievement that moved her to tears. Dr Sean Pittock, chair of neurology at Mayo Clinic, stated that the results offer tremendous hope for people living with this disease. However, he emphasized that much remains to be learned about whether these improvements will sustain over time.
Broader implications and context
Celine Dion announced her diagnosis in December 2022, explaining that the condition affected every aspect of her daily life, including her voice. Yasmin Sheikh, head of policy at Anthony Nolan, a blood cancer charity not involved in the trial, called the research an exciting development. She provided more evidence that CAR-T therapies could have applications beyond blood cancer. The study demonstrates potential for other immune-mediated neurologic conditions where effective options remain limited. While the current data shows significant functional recovery, the long-term durability of the response is still unknown. Researchers continue to monitor patients to determine if the initial gains persist. This opens an exciting new avenue for the field, though the full scope of its impact awaits further investigation.
